<DOC>
	<DOCNO>NCT00871403</DOCNO>
	<brief_summary>The main purpose study determine whether combination pazopanib pemetrexed safe effective treatment advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Study Pazopanib Pemetrexed Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Written inform consent At least 18 year old Histologically cytologicallyconfirmed diagnosis predominantly nonsquamous cell Stage IIIBwet ( confirm malignant pleural effusion ) Stage IV NSCLC No prior systemic firstline therapy advance NSCLC Measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 12 week Able swallow retain oral medication Adequate organ system function ( hematological , hepatic , renal ) Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) OR childbearing potential , agree use adequate contraception . A male female partner childbearing potential eligible us barrier method contraception abstinence study Active malignancy malignancy 3 year prior first dose study drug NSCLC Central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except asymptomatic , previously treat CNS metastases Clinically significant gastrointestinal abnormality Prolongation correct QT interval ( QTc ) &gt; 480 msecs History one cardiovascular condition within past 6 month prior randomization Poorly control hypertension History cerebrovascular accident ( include transient ischemic attack ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month Major surgery trauma within 28 day nonhealing wound , fracture , ulcer Evidence active bleeding bleeding diathesis Recent hemoptysis Endobronchial lesion and/or lesion infiltrate major pulmonary vessel Serious and/or unstable preexist medical ( e.g. , uncontrolled infection ) , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure Use prohibit medication Use investigational agent within 28 day 5 halflives , whichever longer , prior first dose study drug Ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity except alopecia Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib , pemetrexed , and/or cisplatin Inability interrupt aspirin nonsteroidal antiinflammatory drug study Inability unwillingness take folic acid , vitamin B12 supplementation , dexamethasone Clinically significant thirdspace fluid collection ( e.g. , ascites pleural effusion ) control drainage procedure prior study start Recent concurrent yellow fever vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>GW786034</keyword>
	<keyword>pazopanib</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>cisplatin</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>